STAT1 Regulates MD-2 Expression in Monocytes of Sepsis via miR-30a

Inflammation

Volumn 37, Issue 6, 2014, Pages 1903-1911

  Wang, Yanhong ^a   Li, Tiehua ^a   Wu, Benquan ^a   Liu, Hui ^a   Luo, Jinmei ^a   Feng, Dingyun ^a   Shi, Yunfeng ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

MD 2; miR 30a; monocytes; sepsis; STAT1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; LY96 PROTEIN, HUMAN; MICRORNA; MIRN30 MICRORNA, HUMAN; PROTEIN MD 2; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN;

BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MONOCYTE; PHYSIOLOGY; SEPSIS;

CELL LINE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; LYMPHOCYTE ANTIGEN 96; MICRORNAS; MONOCYTES; SEPSIS; STAT1 TRANSCRIPTION FACTOR;

EID: 84937568057     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9922-1     Document Type: Article

References (29)

1. Liesenfeld, O., L. Lehman, K.P. Hunfeld, and G. Kost. 2014. Molecular diagnosis of sepsis: new aspects and recent developments. Eur J Microbiol Immunol (Bp) 4(1): 1–25.
2. López-Abarrategui, C., A. Del Monte-Martínez, O. Reyes-Acosta, O.L. Franco, and A.J. Otero-González. 2013. LPS inmobilization on porous and non-porous supports as an approach for the isolation of anti-LPS host-defense peptides. Frontiers in Microbiology 4: 389.
3. Florescu, D.F., and A.C. Kalil. 2014. The complex link between influenza and severe sepsis. Virulence 5(1): 137–142.
4. Hotchkiss, R.S., G. Monneret, and D. Payen. 2013. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature Reviews. Immunology 13(12): 862–874.
5. Boomer, J.S., J.M. Green, and R.S. Hotchkiss. 2014. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 5(1): 45–56.
6. Park, B.S., and J.O. Lee. 2013. Recognition of lipopolysaccharide pattern by TLR4 complexes. Experimental & Molecular Medicine 45: e66.
7. Christiansen, D., O.L. Brekke, J. Stenvik, J.D. Lambris, T. Espevik, and T.E. Mollnes. 2012. Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Advances in Experimental Medicine and Biology 946: 237–251.
8. Kimoto, M., K. Nagasawa, and K. Miyake. 2003. Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scandinavian Journal of Infectious Diseases 35(9): 568–572.
9. Miyake, K. 2003. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. International Immunopharmacology 3(1): 119–128.
10. Vandooren, J., P.E. Van den Steen, and G. Opdenakker. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Critical Reviews in Biochemistry and Molecular Biology 48(3): 222–272.
11. Sinkovics, J.G. 2012. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). International Journal of Oncology 40(2): 305–349.
12. Ivády, B., B.J. Béres, and D. Szabó. 2011. Recent advances in sepsis research: novel biomarkers and therapeutic targets. Current Medicinal Chemistry 18(21): 3211–3225.
13. Reid, G., M.B. Kirschner, and N. van Zandwijk. 2011. Circulating microRNAs: association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology 80(2): 193–208.
14. Hennessy, E.J., A.E. Parker, and L.A. O’Neill. 2010. Targeting Toll-like receptors: emerging therapeutics? Nature Reviews. Drug Discovery 9(4): 293–307.
15. Biswas, S.K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends in Immunology 30(10): 475–487.
16. Wang, H.J., J. Deng, J.Y. Wang, P.J. Zhang, Z. Xin, K. Xiao, D. Feng, Y.H. Jia, Y.N. Liu, and L.X. Xie. 2014. Serum miR-122 levels are related to coagulation disorders in sepsis patients. Clinical Chemistry and Laboratory Medicine 14: 1–7.
17. Wang, Z.H., Y.B. Liang, H. Tang, Z.B. Chen, Z.Y. Li, X.C. Hu, and Z.F. Ma. 2013. Dexamethasone down-regulates the expression of microRNA-155 in the livers of septic mice. PloS One 8(11): e80547.
18. Ma, Y., D. Vilanova, K. Atalar, O. Delfour, J. Edgeworth, M. Ostermann, M. Hernandez-Fuentes, S. Razafimahatratra, B. Michot, D.H. Persing, I. Ziegler, B. Törös, P. Mölling, P. Olcén, R. Beale, and G.M. Lord. 2013. Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PloS One 8(10): e75918.
19. Wu Y, Yang L, Mei X, Yu Y. Selective inhibition of STAT1 reduces spinal cord injury in mice. Neurosci Lett. 2013.
20. Trilling, M., V.T. Le, J. Rashidi-Alavijeh, B. Katschinski, J. Scheller, S. Rose-John, G.E. Androsiac, S. Jonjic, V. Poli, K. Pfeffer, and H. Hengel. 2014. “Activated” STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. Journal of Immunology 192(1): 447–458.
21. Lin, L., J. Hou, F. Ma, P. Wang, X. Liu, N. Li, J. Wang, Q. Wang, and X. Cao. 2013. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. Journal of Immunology 191(7): 3896–3904.
22. Nieminen, J.K., M. Niemi, T. Sipponen, H.M. Salo, P. Klemetti, M. Färkkilä, J. Vakkila, and O. Vaarala. 2013. Dendritic cells from Crohn’s disease patients show aberrant STAT1 and STAT3 signaling. PloS One 8(8): e70738.
23. Meisch, J.P., R.M. Vogel, D.M. Schlatzer, X. Li, M.R. Chance, and A.D. Levine. 2013. Human β-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokine synthesis in T cells. Journal of Leukocyte Biology 94(3): 459–471.
24. Singh, U.P., N.P. Singh, H. Guan, B. Busbee, R.L. Price, D.D. Taub, M.K. Mishra, R. Fayad, M. Nagarkatti, and P.S. Nagarkatti. 2013. Leptin antagonist ameliorates chronic colitis in IL-10−/− mice. Immunobiology 218(12): 1439–1451.
25. Fontan, L., and A. Melnick. 2013. Discovering what makes STAT signaling TYK in T-ALL. Cancer Discov 3(5): 494–496.
26. Haque, A., N. Koide, E. Odkhuu, B. Tsolmongyn, Y. Naiki, T. Komatsu, T. Yoshida, and T. Yokochi. 2014. Mouse pyrin and HIN domain family member 1 (pyhin1) protein positively regulates LPS-induced IFN-β and NO production in macrophages. Innate Immunity 20(1): 40–48.
27. Pattison, M.J., K.F. MacKenzie, S.E. Elcombe, and J.S. Arthur. 2013. IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages. FEBS Letters 587(10): 1496–1503.
28. Matsukawa, A. 2007. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Medica Okayama 61(5): 239–245.
29. Klinman, D.M., D. Tross, S. Klaschik, H. Shirota, and T. Sato. 2009. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals of the New York Academy of Sciences 1175: 80–88.